Krebs Biochemicals & Industries Ltd-$
Krebs Biochemicals & Industries Ltd-$ (KREBSBIO) last reported results for the quarter ended Jun 2026, with sales of ₹6.98 crore and net profit of ₹-2.48 crore. The stock last traded at ₹64.1, a market capitalisation of ₹138 crore. Over the past 52 weeks the stock has ranged between ₹38.3 and ₹76.8. Figures are as of 6 Oct 2026 and are not real time.
Krebs Biochemicals & Industries Ltd-$ share price and key metrics
- Current price
- ₹64.1
- Market cap
- ₹138 cr
- Book value
- ₹-75.5
- ROE
- %
- ROCE
- -15.4%
- Dividend yield
- 0.00%
- 52w high / low
- 76.8/38.3
Metrics as of 6 Oct 2026. Not real time.
Track Krebs Biochemicals & Industries Ltd-$
Cruxal reads every Krebs Biochemicals & Industries Ltd-$ filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Krebs Biochemicals & Industries Ltd-$ growth and returns
- 10 Years
- 35%
- 5 Years
- -15%
- 3 Years
- -23%
- TTM
- -30%
- 10 Years
- 0%
- 5 Years
- 7%
- 3 Years
- 10%
- TTM
- 48%
- 10 Years
- -3%
- 5 Years
- -19%
- 3 Years
- -2%
- 1 Year
- -11%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- Last Year
- %
Krebs Biochemicals & Industries Ltd-$ quarterly results
In the quarter ended Jun 2026, sales were ₹6.98 cr, up 27.4% from ₹5.48 cr a year earlier. Net profit was ₹-2.48 cr, up 53.4% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 12.86 | 11.47 | 6.1 | 5.48 | 4.17 | 7.27 | 6.81 | 6.98 |
| Expenses | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 | 6.97 | 7.67 | 6.16 |
| Operating profit | -2.72 | -4.71 | -5.41 | -2.09 | -2.8 | 0.3 | -0.86 | 0.82 |
| OPM % | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% | 4.13% | -12.63% | 11.75% |
| Other income | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 | 0 | 2 | 0.16 |
| Interest | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 | 1.79 | 1.91 | 1.88 |
| Depreciation | 1.71 | 1.72 | 1.57 | 1.6 | 1.62 | 1.63 | 1.57 | 1.59 |
| Profit before tax | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 | -3.12 | -2.34 | -2.49 |
| Tax % | 0.00% | 0.00% | 0.24% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net profit | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 | -3.13 | -2.34 | -2.48 |
| EPS (₹) | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 | -1.45 | -1.09 | -1.15 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Krebs Biochemicals & Industries Ltd-$ annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 24 | 25 |
| Operating profit | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -5 | -3 |
| OPM % | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -23% | -10% |
| Net profit | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -17 | -14 |
| EPS (₹) | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -7.85 | -6.54 |
TTM is the trailing twelve months to the most recent quarter.
Krebs Biochemicals & Industries Ltd-$ balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -184 |
| Borrowings | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 225 |
| Other liabilities | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 101 |
| Total liabilities | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
| Fixed assets | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 142 |
| CWIP | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 2 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total assets | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 163 |
As reported by the company. Total assets equal total liabilities by construction.
Krebs Biochemicals & Industries Ltd-$ cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -11 | -6 | 4 | -36 | -15 | -17 | -25 | 2 | -8 | -2 |
| Cash from investing | -5 | -3 | -4 | -10 | -23 | -23 | -13 | -8 | -5 | -4 |
| Cash from financing | 16 | 9 | 17 | 29 | 38 | 40 | 37 | 6 | 13 | 6 |
| Net cash flow | -0 | 0 | 17 | -17 | 1 | -1 | -0 | 0 | 0 | -0 |
| Free cash flow | -17 | -9 | -1 | -45 | -40 | -41 | -36 | -5 | -11 | -5 |
| CFO / operating profit | 140% | 83% | -40% | 191% | 83% | 51% | 157% | -27% | 52% | 35% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Krebs Biochemicals & Industries Ltd-$ operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% | -15% |
| Debtor days | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | 0 |
| Inventory days | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | — |
| Days payable | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | — |
| Cash conversion cycle | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | 0 |
| Working capital days | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | -1,593 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Krebs Biochemicals & Industries Ltd-$ shareholding pattern
Promoters held 72.74% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.50%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% | 72.74% |
| FIIs | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% | 0.50% |
| Public | 26.76% | 26.76% | 26.75% | 26.76% | 26.76% | 26.76% | 26.77% | 26.76% |
| No. of shareholders | 9,425 | 9,091 | 8,798 | 9,118 | 8,912 | 8,710 | 8,553 | 8,521 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Krebs Biochemicals & Industries Ltd-$ corporate filings
- The Company has enclosed herewith certificates recived from RTA under reg 74 (5)Company Updatelow impact
- Corporate Voting Results Confirm Passage of All Resolutions at Krebs Biochemicals' 34th AGMAGM/EGMlow impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited announced the successful passing of all five…
Read the full analysis - Krebs Biochemicals & Industries Limited concludes 34th Annual General Meeting; seeks approval for related party transactions with Ipca LaboratoriesAGM/EGMlow impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited has successfully concluded its 34th Annual…
Read the full analysis - The Company has enclosed herewith intimation for closure of trading window for the quarter ended 30.09.2026.Insider Trading / SASTlow impact
- Krebs Biochemicals & Industries Limited Announces 34th Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited has issued a formal notice for its 34th Annual…
Read the full analysis - Krebs Biochemicals & Industries Limited Announces 34th AGM and Seeks Approval for INR 120 Crore Related Party Transactions with Ipca LaboratoriesAGM/EGMmedium impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited has scheduled its 34th Annual General Meeting for…
Read the full analysis - Krebs Biochemicals & Industries Ltd files Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: The company has submitted its Annual Report for the financial year ended 31st March 2026…
Read the full analysis - Krebs Biochemicals & Industries Limited announces 34th Annual General Meeting for September 29, 2026Company Updatelow impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited has issued a formal notice for its 34th Annual…
Read the full analysis - Krebs Biochemicals & Industries Limited Reports Net Loss of 2.48 crore for Q1 FY2027Company Updatemedium impact
Cruxal's analysis: Krebs Biochemicals & Industries Limited reported a net loss of 2.48 crore for the quarter…
Read the full analysis - Krebs Biochemicals reports Q1 FY27 net loss of 2.48 crore amid ongoing manufacturing suspensionBoard Meetinglow impact
Cruxal's analysis: Krebs Biochemicals and Industries Limited reported a net loss of 2.48 crore for the…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.